High levels of drug-resistant human immunodeficiency virus variants in patients exhibiting increasing CD4+ T cell counts despite virologic failure of protease inhibitor-containing antiretroviral combination therapy

Journal of Infectious Diseases

Volumn 181, Issue 5, 2000, Pages 1808-1812

  Bélec, Laurent ^a,b,d   Piketty, Christophe ^a   Si Mohamed, Ali ^a   Goujon, Christophe ^c   Hallouin, Marie Charlotte ^a   Cotigny, Sylvie ^a   Weiss, Laurence ^a,b   Kazatchkine, Michel D ^a,b  

^a SORBONNE UNIVERSITÉ   (France)

^b INSERM   (France)

^c HÔPITAL ROTHSCHILD   (France)

^d HÔPITAL BROUSSAIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; PROTEINASE; PROTEINASE INHIBITOR; VIRUS RNA;

AMINO ACID SEQUENCE; ARTICLE; CLINICAL ARTICLE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; STRUCTURAL GENE; T LYMPHOCYTE; TREATMENT FAILURE; VIRUS LOAD; VIRUS MUTANT; VIRUS RESISTANCE;

AMINO ACID SEQUENCE; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; GENE PRODUCTS, POL; GENES, POL; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MUTATION; RNA, VIRAL; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY, AMINO ACID; TIME FACTORS; TREATMENT FAILURE;

EID: 0034043998     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315429     Document Type: Article

References (15)

1. 1. Kaufmann D, Pantaleo G, Sudre P, Telenti A. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study. Lancet 1998;351:723-4.
2. 2. Piketty C, Castiel P, Bélec L, et al. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease. AIDS 1998;12:745-50.
3. 3. Renaud M, Katlama C, Mallet A, et al. Determinants of paradoxical CD4 cell reconstitution after protease inhibitor -containing antiretroviral regimen. AIDS 1999;13:669-76.
4. 4. Grabar S, Costagliola D. Clinical outcomes of patients under HAART with discordant response to CD4 and viral load at 6 months [abstract 169]. In: Programs and abstracts of the 6th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, Virginia: Foundation for Retrovirology and Human Health, 1999:99.
5. 5. Deeks S, Hoh R, Hanley MB, et al. T-cell turnover kinetics in patients with sustained CD4 cell response after experiencing virologic failure of a protease inhibitor-based regimen [abstract LB2]. In: Programs and abstracts of the 6th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, Virginia: Foundation for Retrovirology and Human Health, 1999: 205.
6. + T cells and decreases their susceptibility to apoptosis in vitro and in vivo. Blood 1999;94:1021-7.
7. 7. Faye A, Race E, Obry V, et al. Viral fitness in patients with discordant CD4 and plasma HIV RNA evolution following protease inhibitor failure [abstract 331]. In: Programs and abstracts of the 6th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, Virginia: Foundation for Retrovirology and Human Health, 1999:130.
8. 8. Stoddart C, Mammano F, Moreno M, et al. Lack of fitness of protease inhibitor-resistance HIV-1 in vivo [abstract 4]. In: Programs and abstracts of the 6th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, Virginia: Foundation for Retrovirology and Human Health, 1999:67.
9. 9. Nijhuis M, Boucher CA, Schipper P, Leitner T, Shuurman R, Albert J. Stochastic process strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy. Proc Natl Acad Sci USA 1998;95:14441-6.
10. 10. Condra JH, Holder DJ, Schleif WA, et al. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol 1996;70:8270-6.
11. 11. Hirsch MS, Conway B, D'Aquila R, et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. JAMA 1998;279:1984-91.
12. 12. Condra JH. Resistance to protease inhibitors of HIV. Haemophilia 1998;4: 610-5.
13. 13. Kozal MJ, Shah N, Shen N, et al. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat Med 1996;2:753-9.
14. 14. Havlir D, Hellmann N, Petropoulous C, et al. Viral rebound in the presence of indinavir without protease inhibitor resistance [abstract LB12]. In: Programs and abstracts of the 6th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, Virginia: Foundation for Retrovirology and Human Health, 1999:207.
15. 15. Weiss L, Cahen Y, Girard PM. Incomplete IL-2 response but restoration of T cell reactivity to CMV antigens in patients exhibiting discordant immunological and virological responses under HAART [abstract 66]. In: Program and abstracts of the 4th European Conference on AIDS Research (Tempere, Finland). Kalamazoo, Michigan: Pharmacia and Upjohn, 1999: 66.